Midostaurin: First Global Approval

被引：80

作者：

Kim, Esther S. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2017年 / 77卷 / 11期

关键词：

ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; ADULT PATIENTS; PHASE-I; PKC412; FLT3; COMBINATION; TRIAL; CELLS;

D O I：

10.1007/s40265-017-0779-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Midostaurin (Rydapt(A (R))) is a multikinase inhibitor being developed by Novartis Pharmaceuticals. In April 2017, midostaurin was approved in the USA for the treatment of adult patients with newly diagnosed, FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukaemia (AML) [in combination with standard cytarabine and daunorubicin induction, and cytarabine consolidation], or aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL) [collectively known as advanced SM]. The article summarizes the milestones in the development of midostaurin leading to this first global approval.

引用

页码：1251 / 1259

页数：9

共 23 条

[1]

Adis Insight, 2017, DRUG PROF MID

[2] A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients [J].

Cooper, Brenda W. ;

Kindwall-Keller, Tamila L. ;

Craig, Michael D. ;

Creger, Richard J. ;

Hamadani, Mehdi ;

Tse, William W. ;

Lazarus, Hillard M. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07) :428-432

[3]

Daver N, 2014, TARGETED THERAPY ACU, P215

[4] Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers [J].

del Corral, Adam ;

Dutreix, Catherine ;

Huntsman-Labed, Alice ;

Lorenzo, Sebastien ;

Morganroth, Joel ;

Harrell, Robert ;

Wang, Yanfeng .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) :1255-1263

[5] An update of current treatments for adult acute myeloid leukemia [J].

Dombret, Herve ;

Gardin, Claude .

BLOOD, 2016, 127 (01) :53-61

[6] Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3 [J].

Fischer, Thomas ;

Stone, Richard M. ;

DeAngelo, Daniel J. ;

Galinsky, Ilene ;

Estey, Elihu ;

Lanza, Carlo ;

Fox, Edward ;

Ehninger, Gerhard ;

Feldman, Eric J. ;

Schiller, Gary J. ;

Klimek, Virginia M. ;

Nimer, Stephen D. ;

Gilliland, D. Gary ;

Dutreix, Catherine ;

Huntsman-Labed, Alice ;

Virkus, Jodi ;

Giles, Francis J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) :4339-4345

[7]

Gotlib J., 2010, Blood, V116

[8] Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis [J].

Gotlib, Jason ;

Kluin-Nelemans, Hanneke C. ;

George, Tracy I. ;

Akin, Cem ;

Sotlar, Karl ;

Hermine, Olivier ;

Awan, Farrukh T. ;

Hexner, Elizabeth ;

Mauro, Michael J. ;

Sternberg, David W. ;

Villeneuve, Matthieu ;

Labed, Alice Huntsman ;

Stanek, Eric J. ;

Hartmann, Karin ;

Horny, Hans-Peter ;

Valent, Peter ;

Reiter, Andreas .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (26) :2530-2541

[9]

Maziarz RT, 2016, BLOOD, V128

[10]

Motyckova G., 2015, Targeted Therapy of Acute Myeloid Leukemia, VVolume 2014, P201

← 1 2 3 →